UNCY
Unicycive Therapeutics, Inc.Healthcare·Biotechnology
$7.38
$159M market cap
Revenue
$0.0M
Free Cash Flow
$-14.3M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
2-Year Price History
$8.08+4.1%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -8.4 | -8.4 | -12.8 | -6.2 | -6.3 | -0.0 | 54.6 | 0.8 | 239.1 | -187.7% | -- | -- |
| Act | 2025-Q4 | 0.0 | -14.5 | -7.2 | -14.7 | -8.0 | -8.0 | -0.0 | 41.3 | 0.1 | 158.9 | -291.0% | -536.7x | -- |
Valuation & Metrics
Market Stats
Price$7.38
Market Cap$159M
Enterprise Value$105M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-9.0%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-27.5M
Free Cash Flow$-14.3M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-239.3%
WC Change % Rev0.0%
Interest Coverage-849.1x
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares2.2M
Days to Cover4.6
Change (vs Prior)-0.5%
Need at least 2 settlement dates for chart
Employees
Headcount22
Revenue / Employee$0
Gross Profit / Employee$-9,591
Cash Runway
45.9months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
33.2%(+20.0% YoY)
40 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
5.7%(+3.7% YoY)
8 filers
Vanguard, iShares, SPDR
Market makers
1.2%(+1.2% YoY)
3 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| Vivo Capital, LLC | $11.8M | $4.62 | +$0 | +$11.8M | -6.9% | $1.20B |
| MILLENNIUM MANAGEMENT LLC | $9.2M | $5.99 | +$2.5M | +$9.2M | -0.5% | $127.40B |
| Octagon Capital Advisors LP | $6.6M | $4.77 | +$0 | +$6.6M | +1.0% | $904M |
| Nantahala Capital Management, LLC | $6.2M | $4.77 | +$0 | +$6.2M | -2.4% | $1.60B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $5.3M | $6.58 | +$5.3M | +$5.3M | — | $4.04T |
| GREAT POINT PARTNERS LLC | $5.2M | $4.77 | +$0 | +$5.2M | -4.5% | $408M |
| Logos Global Management LP | $3.1M | $4.77 | +$0 | +$3.1M | -1.6% | $1.94B |
| CITADEL ADVISORS LLC | $1.6M | $5.54 | −$141K | +$1.6M | -0.4% | $138.22B |
| Integral Health Asset Management, LLC | $1.5M | $6.58 | +$1.5M | +$1.5M | -0.5% | $1.64B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $1.3M | $5.15 | +$214K | +$1.3M | +2.3% | $1.61T |
| SUSQUEHANNA INTERNATIONAL GROUP, LLPMM | $1.3M | $6.48 | +$1.1M | +$1.3M | -0.6% | $77.14B |
| MORGAN STANLEY | $1.2M | $6.30 | +$932K | +$1.2M | -0.3% | $1.65T |
| MARSHALL WACE, LLP | $1.0M | $6.58 | +$1.0M | +$1.0M | +0.6% | $92.71B |
| Dauntless Investment Group, LLC | $968K | $6.09 | +$379K | +$968K | +4.7% | $35.6M |
| DIMENSIONAL FUND ADVISORS LPPassive | $940K | $6.58 | +$941K | +$940K | -0.4% | $480.92B |
| BNP PARIBAS FINANCIAL MARKETS | $787K | $5.90 | +$130K | +$787K | -0.2% | $149.31B |
| DIADEMA PARTNERS LP | $698K | $6.58 | +$698K | +$698K | +2.6% | $224M |
| VANGUARD FIDUCIARY TRUST COPassive | $665K | $6.58 | +$665K | +$665K | — | $395.83B |
| Diametric Capital, LP | $529K | $6.58 | +$529K | +$529K | +1.1% | $381M |
| STATE STREET CORPPassive | $527K | $5.02 | +$97K | +$527K | -0.2% | $2.89T |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
-1.93%
avg per quarter
Holders (ex-self)
-1.91%
excl. this stock
Buyers (this Q)
+1.90%
28 buyers · $0.02B in
Sellers (this Q)
-2.23%
13 sellers · $0.00B out
alpha coverage: 91% of $ has a lifetime-alpha record
Holder behavior (holder profile)source: holder
On big dips (−10%+)
-6.6%
how holders react when this stock falls
On quiet Qs
+10.0%
−10% to +10% baseline
On rallies (+10%+)
+2.3%
how they react when this stock rises
Holders' portfolio flow this Q
-7.0%
outflows — trims may be forced
Sellers' portfolio flow this Q
+1.9%
Sellers grew AUM elsewhere — opinionated cut of this stock.
Biggest decreases this quarter
New buyers this quarter
VANGUARD CAPITAL MANAGEMENT LLC+$0.01BIntegral Health Asset Management, LLC+$0.00Bα-0.5MARSHALL WACE, LLP+$0.00Bα+0.6DIMENSIONAL FUND ADVISORS LP+$0.00Bα-0.4DIADEMA PARTNERS LP+$0.00Bα+2.6VANGUARD FIDUCIARY TRUST CO+$0.00BDiametric Capital, LP+$0.00Bα+1.1JANE STREET GROUP, LLC+$0.00Bα-0.1Seven Fleet Capital Management LP+$0.00Bα+44.7
Top-5 holders · 59.9%
Vivo Capital, LLC--
MILLENNIUM MANAGEMENT LLC--
Octagon Capital Advisors LP--
Nantahala Capital Management, LLC--
VANGUARD CAPITAL MANAGEMENT LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
Vivo Capital, LLC1.8MMILLENNIUM MANAGEMENT LLC1.4MOctagon Capital Advisors LP1.0MNantahala Capital Management, LLC939KGREAT POINT PARTNERS LLC797KLogos Global Management LP474KCITADEL ADVISORS LLC237KIntegral Health Asset Management, LLC225KMORGAN STANLEY188KCANTOR FITZGERALD, L. P.75K
Analyst Coverage
Analyst Coverage
Analyst Ratings
6
Buy: 6Consensus: Buy
Corporate
Order Flow (FINRA, ~3w lag)
37.8%retail+2.8pp
15.8%dark-0.5pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Unicycive Therapeutics: Regulatory Litigations and Relentless Dilution
Overall Risk
9/10
Fraud
6/10
Dilution
10/10
Insolvency
4/10
Earnings Overstated
7/10
Hidden Liabilities
8/10
Legal
9/10
Audit Warnings
3/10
Hidden Upside
2/10
Contextually Acceptable
2/10